ICCS 2025 - Presenting Companies
|
Presented by:
|
Charite, Germany |
|
T-knife is a biotech company dedicated to developing T cell receptor-based immunotherapies that deliver broad, deep and durable responses to solid tumor cancer patients. Focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), the company’s unique approach leverages its proprietary platforms and synthetic biology capabilities to design the next-generation of Supercharged T cell therapies with best-in-class potential.
The company’s lead program, TK-6302, is a Supercharged PRAME targeting TCR-T rationally designed with novel enhancements to improve T cell fitness and persistence and to overcome the immunosuppressive tumor micro-environment. The company plans to submit a clinical trial application (CTA) in the fall of 2025 to initiate a Phase 1/2 clinical study of TK-6302 in 2026. T-knife was founded by leading T cell and immunology experts utilizing technology developed at the Max Delbrück Center for Molecular Medicine together with the Charité – Universitätsmedizin Berlin, is led by an experienced management team, and is supported by a leading group of international investors, including Andera Partners, EQT Life Sciences, RA Capital Management and Versant Ventures. T-knife is seeking investors for its next private financing round. |
Company: T-knife Therapeutics
Speaker: Elisa Kieback Title: CTO and Co-Founder E.: [email protected] www.t-knife.com |
|
Presented by:
|
The Wistar Institute, USA |
|
Chimeron Bio is at the forefront of cancer innovation, advancing a new era of genetic medicine to address the limitations of today’s cancer therapies—namely, poor tissue targeting, short duration of therapeutic effect, toxicity, and manufacturing barriers that restrict patient access.
Powered by our proprietary, next-generation self-amplifying RNA (saRNA) platform—100 to 1000 times more potent than LNP-based mRNA—we are developing multi-agent therapies including in vivo CAR-T, novel immuno-oncology solutions, and next-generation cancer vaccines. Our industry-leading team brings deep expertise and a proven track record in building and launching transformational therapeutic platforms. At Chimeron Bio, we are committed to delivering powerful, precise, and accessible cancer treatments to patients worldwide. |
|
Monarch Therapeutics is an adoptive cell therapy company that is revolutionizing cell therapies.
With a focus on solid tumors, Monarch Therapeutics implements its universal platform which works to eliminate tumors that are targeted by its differentiated adaptors that enable industry leading tunability, multiplexing, and control. Monarch Therapeutics is set to drive multiple pipeline candidates through IND-enabling studies. |
Company: Monarch Therapeutics
Speaker: Christopher Potts Title: CEO E.: [email protected] www.monarchtherapeutics.com |
|
AlterBio was established on the philosophy that cancer is a disease of tissues, solid tumors being the most complex disease with the largest significant unmet need for new treatments.
Our proprietary Tranzformers Universal Adapter-CAR+ Activator platform combines the best aspects of in vivo cell engineering with antibody therapeutics to alter the tumor microenvironment through in vivo synthetic biology. Locoregional delivery of Tranzformer therapeutics enables tumor targeting with unprecedented control and addresses all the current liabilities associated with current solid tumor therapies. AlterBio is currently raising seed capital. |
|
Presented by:
|
Biopôle, Switzerland |
|
Limula offers a solution to make personalised cell therapies commercially viable.
The team combines decades of experience in precision engineering, life science tools commercialisation and process development to offer a solution enabling every step of cell therapy manufacturing in a single instrument, directly at the point of care, significantly impacting production costs by reducing the need for skilled labour, equipment and high-grade clean room infrastructure. Limula is now providing early access to its technology to collect data and user feedback, with traction from hospital GMP-facilities looking for a cost-efficient solution for their clinical trials and biopharma companies aiming at increasing their throughput with automation. Limula is raising a 20m Series A round to grow revenues and scale product manufacturing towards full deployment. |
|
Presented by:
|
MatWin, France |
|
Pan Cancer T’s mission is to empower patients' own immune cells to cure their cancer by developing pioneering T cell receptor (TCR)-T cell therapies for solid cancers. Our first product, PCT1:CO-STIM, features an IP-protected TCR against a novel target, ROPN1, expressed in >90% of triple negative breast cancer (TNBC) patients. It also incorporates our proprietary TCR:CO-STIM technology to overcome the hostile solid tumor microenvironment that limits cell therapy effectiveness.
We are seeking equity funding to generate clinical data for our lead asset in TNBC, with plans to begin treating patients at the start of 2027. Additionally, we aim to advance our solid cancer pipeline and seek partnership deals with pharmaceutical and larger biotech companies. |
Company: Pan Cancer T
Speaker: Rachel Abbott Title: CEO E.: [email protected][email protected] www.pancancer-t.com |
|
Presented by:
|
Oslo Cancer Cluster, Norway
|
|
Strike Pharma is founded on a technology platform for targeted nanoparticle delivery, enabling in vivo CAR-T therapy. Compared to current CAR-T therapy this offers an off-the-shelf treatment, with no delays, no need for preconditioning or gene modification, potential for repeated treatment, at a fraction of the cost.
The Strike technology for affinity conjugation allows for separate storage of LNP and the T-cell targeting mAb. To this end Strike develops an LNP-based anti-CD19 in vivo CAR-T for DLBCL, currently in preclinical research phase and the company is looking for research collaborations and potentially further funding. |
Company: Strike Pharma
Speaker: Per Norlen Title: CEO, MD, PhD E.: [email protected] www.strikepharma.com |
|
Anocca is a rapidly growing, privately held Swedish biotechnology company focused on the development of TCR-T cell therapies in oncology using its unique deep tech platform built for precision mapping of T-cell targets, and generation, characterization and optimization of targeted TCR-T products. Based on standardized and automated analyses of engineered human cells, enabled by a set of unique biotechnologies and powered by a proprietary software ecosystem, our discovery engine fuels scalable development of TCR-T cell therapies to address the immense and unaddressed target space in solid tumors.
The Anocca platform has generated over 40 high-value preclinical TCR assets and its first TCR-T product, manufactured using non-viral gene editing in its in-house cGMP manufacturing facility, targets mutant KRAS in advanced pancreatic cancer and is about to enter clinical development in Europe. Anocca is seeking to build relationships with strategic partners committed to the development of innovative T-cell therapies, with a focus on collaborative R&D partnerships with biopharma companies for the development and commercialization of TCR-T products in oncology. |
Company: Anocca
Speaker: Mark Farmery Title: Chief Development Officer E.: [email protected] www.anocca.com |
|
TILT Biotherapeutics (Tiltbio) is a clinical-stage biotech company advancing next-generation immunotherapies for solid tumors, with an initial focus on platinum-resistant ovarian cancer.
Its patented TILT® technology uses intravenously delivered modified viruses to reprogram the tumor microenvironment and enhance immune responses, boosting the efficacy of T-cell therapies and checkpoint inhibitors. Lead candidate TILT-123 is in Phase 2 stage. Phase 1 trials as both monotherapy and in combination with ICIs or TILs, with over 80 patients treated to date show excellent safety and promising activity. Next Tiltbio will seek Series C funding and strategic collaborations for TILT-123 development, as well as partnerships in T-cell therapy space or out-licensing of its preclinical oncolytic virus assets. |
Company: TILT Biotherapeutics
Speaker: Aino Kalervo Title: Chief Operating Officer E.: [email protected] www.tiltbio.com |
|
Presented by:
|
OBN, UK |
|
ImmunoKey is a seed-stage UK biotechnology company developing a first-in-class platform technology to unlock the potential of CAR T-cell therapy for solid cancers.
Our pipeline is built around the CARKey™ platform, that enables maximal tumour coverage and reduced antigen escape through multi-antigen targeting, whilst minimising harm to healthy tissues. This is complemented by AmpliT™ and ReviT™, technologies that address T-cell exhaustion and the suppressive tumour microenvironment. Backed by a leadership team with proven success in cell therapy development, exit, and clinical implementation, ImmunoKey is poised to unlock new possibilities in cancer immunotherapy. We aim to do this by complementing our in-house development with collaborative and strategic partnerships in product development and clinical advancement. Following a founder’s capital input of £650K, we are seeking funding of up ~£3.2M to produce proof-of-concept and pre-clinical data over 2 years. Download presentation here |
|
Presented by:
|
Cambridge Innovation Partners, USA |
|
InnDura Therapeutics is developing a novel in vivo gene delivery platform that enables high-precision engineering and activation of immune cells directly within the patient.
Our proprietary two-tier system—combining targeted lipid nanoparticles and the immune-activating receptor EVE16—bypasses traditional ex vivo manufacturing, offering improved pharmacokinetics, greater patient accessibility, and significantly reduced treatment costs. This platform has broad therapeutic potential across oncology and autoimmune diseases, and our clinical proof-of-concept will be performed in patients suffering from B-cell leukemias and lymphomas. We are looking for licensing partnerships that will help us bring several therapeutic assets into the clinic. |
Company: InnDura Therapeutics Inc.
Speaker: Nikola A. Ivica PhD Title: Co-Founder and Head of Discovery E.: [email protected] www.inndura.com |
|
iXgene Inc. is a Japanese biotech company developing cell therapies for hard-to-treat cancers. Our lead program, IXG-001, targets glioblastoma, where prognosis remains poor and no major therapeutic advances have been made in decades. Tumor heterogeneity and glioma stem cells (GSCs) drive resistance and recurrence.
IXG-001 is a genome-edited, iPS-derived neural stem cell therapy that locally converts a systemically administered prodrug into a potent chemotherapeutic, achieving high intratumoral drug concentration and broad tumor killing—including GSCs—while minimizing systemic toxicity. Preclinical studies have demonstrated significant tumor regression and survival benefits in mice. We aim to begin Phase 1 trials in Japan in 2026 and a global Phase 2 in 2027. We are currently exploring future co-development and licensing opportunities, and seeking oncology-focused investors for our upcoming Series B/C financing. |
Company: iXgene Inc.
Speaker: Atsushi Mizuno Title: COO, Representative Director E.: [email protected] www.ixgene.inc/en |